About this book
Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages.
Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
"The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise."
Steven T. Rosen, M.D.
Editors and affiliations
- DOI https://doi.org/10.1007/978-0-387-69259-3
- Copyright Information Springer-Verlag New York 2010
- Publisher Name Springer, New York, NY
- eBook Packages Medicine
- Print ISBN 978-0-387-69257-9
- Online ISBN 978-0-387-69259-3
- Series Print ISSN 0927-3042
- Buy this book on publisher's site